QuidelOrtho (QDEL) Competitors

$11.39 +0.34 (+3.08%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$11.46 +0.06 (+0.57%)

As of 07:01 AM Eastern

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

Should you buy QuidelOrtho stock or one of its competitors? MarketBeat compares QuidelOrtho with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with QuidelOrtho include ICU Medical (ICUI), Haemonetics (HAE), DENTSPLY SIRONA (XRAY), Neogen (NEOG), and STAAR Surgical (STAA). These companies are all part of the "health care supplies" industry.

How does QuidelOrtho compare to ICU Medical?

ICU Medical (NASDAQ:ICUI) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, ICU Medical had 10 more articles in the media than QuidelOrtho. MarketBeat recorded 18 mentions for ICU Medical and 8 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.57 beat ICU Medical's score of 0.54 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ICU Medical	5 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.1% of ICU Medical shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 2.1% of ICU Medical shares are held by insiders. Comparatively, 0.8% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ICU Medical has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICU Medical	$2.23B	1.38	$730K	$1.85	66.48
QuidelOrtho	$2.73B	0.28	-$1.13B	-$17.82	N/A

ICU Medical currently has a consensus target price of $169.00, suggesting a potential upside of 37.41%. QuidelOrtho has a consensus target price of $14.88, suggesting a potential upside of 30.60%. Given ICU Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe ICU Medical is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICU Medical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

ICU Medical has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

ICU Medical has a net margin of 2.15% compared to QuidelOrtho's net margin of -45.57%. ICU Medical's return on equity of 7.50% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICU Medical	2.15%	7.50%	3.91%
QuidelOrtho	-45.57%	4.25%	1.56%

Summary

ICU Medical beats QuidelOrtho on 13 of the 17 factors compared between the two stocks.

How does QuidelOrtho compare to Haemonetics?

Haemonetics (NYSE:HAE) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Haemonetics currently has a consensus target price of $79.33, suggesting a potential upside of 38.43%. QuidelOrtho has a consensus target price of $14.88, suggesting a potential upside of 30.60%. Given Haemonetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Haemonetics is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 1.8% of Haemonetics shares are held by insiders. Comparatively, 0.8% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Haemonetics has a net margin of 7.29% compared to QuidelOrtho's net margin of -45.57%. Haemonetics' return on equity of 27.30% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
QuidelOrtho	-45.57%	4.25%	1.56%

In the previous week, Haemonetics had 7 more articles in the media than QuidelOrtho. MarketBeat recorded 15 mentions for Haemonetics and 8 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.57 beat Haemonetics' score of 0.31 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
QuidelOrtho	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.00	$97.31M	$2.02	28.37
QuidelOrtho	$2.73B	0.28	-$1.13B	-$17.82	N/A

Haemonetics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

Summary

Haemonetics beats QuidelOrtho on 14 of the 17 factors compared between the two stocks.

How does QuidelOrtho compare to DENTSPLY SIRONA?

QuidelOrtho (NASDAQ:QDEL) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

QuidelOrtho presently has a consensus target price of $14.88, indicating a potential upside of 30.60%. DENTSPLY SIRONA has a consensus target price of $13.82, indicating a potential upside of 32.74%. Given DENTSPLY SIRONA's stronger consensus rating and higher probable upside, analysts clearly believe DENTSPLY SIRONA is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 0.8% of QuidelOrtho shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DENTSPLY SIRONA has a net margin of -17.06% compared to QuidelOrtho's net margin of -45.57%. DENTSPLY SIRONA's return on equity of 18.83% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-45.57%	4.25%	1.56%
DENTSPLY SIRONA	-17.06%	18.83%	5.13%

In the previous week, QuidelOrtho and QuidelOrtho both had 8 articles in the media. DENTSPLY SIRONA's average media sentiment score of 0.79 beat QuidelOrtho's score of 0.57 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DENTSPLY SIRONA	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DENTSPLY SIRONA has higher revenue and earnings than QuidelOrtho. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.28	-$1.13B	-$17.82	N/A
DENTSPLY SIRONA	$3.68B	0.57	-$598M	-$3.15	N/A

QuidelOrtho has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

DENTSPLY SIRONA beats QuidelOrtho on 12 of the 15 factors compared between the two stocks.

How does QuidelOrtho compare to Neogen?

QuidelOrtho (NASDAQ:QDEL) and Neogen (NASDAQ:NEOG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

QuidelOrtho presently has a consensus target price of $14.88, indicating a potential upside of 30.60%. Neogen has a consensus target price of $10.67, indicating a potential upside of 26.53%. Given QuidelOrtho's higher probable upside, equities research analysts clearly believe QuidelOrtho is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 0.8% of QuidelOrtho shares are owned by company insiders. Comparatively, 0.6% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

QuidelOrtho has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Neogen has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

In the previous week, QuidelOrtho had 1 more articles in the media than Neogen. MarketBeat recorded 8 mentions for QuidelOrtho and 7 mentions for Neogen. Neogen's average media sentiment score of 1.07 beat QuidelOrtho's score of 0.57 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

QuidelOrtho has a net margin of -45.57% compared to Neogen's net margin of -69.93%. QuidelOrtho's return on equity of 4.25% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-45.57%	4.25%	1.56%
Neogen	-69.93%	2.35%	1.46%

Neogen has lower revenue, but higher earnings than QuidelOrtho. Neogen is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.28	-$1.13B	-$17.82	N/A
Neogen	$894.66M	2.05	-$1.09B	-$2.80	N/A

Summary

QuidelOrtho beats Neogen on 9 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to STAAR Surgical?

QuidelOrtho (NASDAQ:QDEL) and STAAR Surgical (NASDAQ:STAA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

QuidelOrtho presently has a consensus target price of $14.88, indicating a potential upside of 30.60%. STAAR Surgical has a consensus target price of $26.69, indicating a potential downside of 16.63%. Given QuidelOrtho's higher probable upside, equities research analysts clearly believe QuidelOrtho is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 0.8% of QuidelOrtho shares are owned by company insiders. Comparatively, 39.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

QuidelOrtho has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

In the previous week, STAAR Surgical had 16 more articles in the media than QuidelOrtho. MarketBeat recorded 24 mentions for STAAR Surgical and 8 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.57 beat STAAR Surgical's score of 0.49 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STAAR Surgical	3 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

STAAR Surgical has a net margin of -7.24% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat STAAR Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-45.57%	4.25%	1.56%
STAAR Surgical	-7.24%	3.33%	2.56%

STAAR Surgical has lower revenue, but higher earnings than QuidelOrtho. STAAR Surgical is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.28	-$1.13B	-$17.82	N/A
STAAR Surgical	$239.44M	6.66	-$80.45M	-$0.43	N/A

Summary

STAAR Surgical beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

Get QuidelOrtho News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QDEL vs. The Competition

Export

Metric	QuidelOrtho	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$753.51M	$8.18B	$6.34B	$12.37B
Dividend Yield	N/A	2.53%	2.80%	5.35%
P/E Ratio	-0.64	15.80	20.66	25.63
Price / Sales	0.28	8.38	547.02	76.59
Price / Cash	0.58	16.82	43.26	56.33
Price / Book	0.42	3.63	9.93	6.97
Net Income	-$1.13B	$223.05M	$3.55B	$333.62M
7 Day Performance	5.46%	-1.07%	1.69%	1.09%
1 Month Performance	-34.88%	1.86%	0.48%	3.08%
1 Year Performance	-65.52%	2.20%	39.38%	35.68%

QuidelOrtho Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QDEL QuidelOrtho	3.68 of 5 stars	$11.39 +3.1%	$14.88 +30.6%	-66.1%	$753.51M	$2.73B	N/A	6,500
ICUI ICU Medical	3.5594 of 5 stars	$118.67 -0.2%	$169.00 +42.4%	-9.5%	$2.97B	$2.23B	5,936.47	13,000	Insider Trade
HAE Haemonetics	4.1625 of 5 stars	$55.23 -6.8%	$82.78 +49.9%	-16.1%	$2.75B	$1.36B	15.22	3,023	Analyst Forecast
XRAY DENTSPLY SIRONA	4.6756 of 5 stars	$11.20 -5.2%	$13.91 +24.2%	-36.7%	$2.37B	$3.68B	N/A	14,000
NEOG Neogen	2.3385 of 5 stars	$9.09 -4.6%	$10.67 +17.3%	+32.1%	$2.07B	$894.66M	N/A	2,110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QDEL) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

QuidelOrtho (QDEL) Competitors

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

How does QuidelOrtho compare to ICU Medical?

Summary

How does QuidelOrtho compare to Haemonetics?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Summary

How does QuidelOrtho compare to Neogen?

Summary

How does QuidelOrtho compare to STAAR Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

QuidelOrtho (QDEL) Competitors

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

How does QuidelOrtho compare to ICU Medical?

Does the media favor ICUI or QDEL?

Do institutionals & insiders hold more shares of ICUI or QDEL?

Which has higher valuation & earnings, ICUI or QDEL?

Do analysts prefer ICUI or QDEL?

Which has more volatility and risk, ICUI or QDEL?

Is ICUI or QDEL more profitable?

Summary

How does QuidelOrtho compare to Haemonetics?

Do analysts prefer HAE or QDEL?

Do institutionals & insiders hold more shares of HAE or QDEL?

Is HAE or QDEL more profitable?

Does the media favor HAE or QDEL?

Which has higher valuation & earnings, HAE or QDEL?

Which has more volatility and risk, HAE or QDEL?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Do analysts recommend QDEL or XRAY?

Do insiders and institutionals believe in QDEL or XRAY?

Is QDEL or XRAY more profitable?

Does the media refer more to QDEL or XRAY?

Which has better earnings and valuation, QDEL or XRAY?

Which has more volatility and risk, QDEL or XRAY?

Summary

How does QuidelOrtho compare to Neogen?

Do analysts recommend QDEL or NEOG?

Do institutionals and insiders believe in QDEL or NEOG?

Which has more risk and volatility, QDEL or NEOG?

Does the media refer more to QDEL or NEOG?

Is QDEL or NEOG more profitable?

Which has preferable earnings & valuation, QDEL or NEOG?

Summary

How does QuidelOrtho compare to STAAR Surgical?

Do analysts recommend QDEL or STAA?

Do institutionals and insiders believe in QDEL or STAA?

Which has more risk and volatility, QDEL or STAA?

Does the media refer more to QDEL or STAA?

Is QDEL or STAA more profitable?

Which has preferable earnings & valuation, QDEL or STAA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools